LINC00589 and breast carcinoma: CCK-8 assays revealed that overexpression of LINC00589 decreased the cell viability of all the six TR SKBR3 cells (Fig. 2A and Supplementary Fig. 5), while knockdown of LINC00589 increased cell viability in WT SKBR3 and BT474 breast cancer cells, which was verified under increasing doses (Supplementary Fig. 6a–c) or times (Fig. 2B, C) of trastuzumab treatment.